Outcomes of patients implanted with a left ventricular assist device at nontransplant mechanical circulatory support centers

Marc R. Katz, Michael G. Dickinson, Nirav Y. Raval, James Slater, David A. Dean, Gary R. Zeevi, Evelyn M. Horn, Arash Salemi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The goal of this study was to assess outcomes of patients who underwent implantation of left ventricular assist devices (LVADs) at nontransplantation mechanical circulatory support centers. As the availability of LVADs for advanced heart failure has expanded to nontransplantation mechanical circulatory support centers, concerns have been expressed about maintaining good outcomes. Demographics and outcomes were evaluated in 276 patients with advanced heart failure who underwent implantation of LVADs as bridge to transplantation or destination therapy at 27 open-heart centers. Baseline characteristics, operative mortality, length of stay, readmission rate, adverse events, quality of life, and survival were analyzed. The overall 30-day mortality was 3% (8 of 276), and survival rates at 6, 12, and 24 months, respectively, were 92 ± 2%, 88 ± 3%, and 84 ± 4% for the bridge-to-transplantation group and 81 ± 3%, 70 ± 5%, and 63 ± 6% for the destination therapy group, comparable with results published by the national Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). The median length of stay for all patients was 21 days. Bleeding was the most frequent adverse event. Stroke occurred in 4% (bridge to transplantation) and 6% (destination therapy) of patients. Quality-of-life measures and 6-minute walk distances showed sustained improvements throughout support. In conclusion, outcomes with LVAD support at open-heart centers are acceptable and comparable with results from the INTERMACS registry. With appropriate teams, training, center commitment, and certification, LVAD therapy is being disseminated in a responsible way to open-heart centers.

Original languageEnglish (US)
Pages (from-to)1254-1259
Number of pages6
JournalAmerican Journal of Cardiology
Volume115
Issue number9
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Heart-Assist Devices
Registries
Transplantation
Length of Stay
Heart Failure
Quality of Life
Mortality
Certification
Group Psychotherapy
Therapeutics
Survival Rate
Stroke
Demography
Hemorrhage
Survival

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Katz, Marc R. ; Dickinson, Michael G. ; Raval, Nirav Y. ; Slater, James ; Dean, David A. ; Zeevi, Gary R. ; Horn, Evelyn M. ; Salemi, Arash. / Outcomes of patients implanted with a left ventricular assist device at nontransplant mechanical circulatory support centers. In: American Journal of Cardiology. 2015 ; Vol. 115, No. 9. pp. 1254-1259.
@article{98f944b322e94e2f883d780745d1face,
title = "Outcomes of patients implanted with a left ventricular assist device at nontransplant mechanical circulatory support centers",
abstract = "The goal of this study was to assess outcomes of patients who underwent implantation of left ventricular assist devices (LVADs) at nontransplantation mechanical circulatory support centers. As the availability of LVADs for advanced heart failure has expanded to nontransplantation mechanical circulatory support centers, concerns have been expressed about maintaining good outcomes. Demographics and outcomes were evaluated in 276 patients with advanced heart failure who underwent implantation of LVADs as bridge to transplantation or destination therapy at 27 open-heart centers. Baseline characteristics, operative mortality, length of stay, readmission rate, adverse events, quality of life, and survival were analyzed. The overall 30-day mortality was 3{\%} (8 of 276), and survival rates at 6, 12, and 24 months, respectively, were 92 ± 2{\%}, 88 ± 3{\%}, and 84 ± 4{\%} for the bridge-to-transplantation group and 81 ± 3{\%}, 70 ± 5{\%}, and 63 ± 6{\%} for the destination therapy group, comparable with results published by the national Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). The median length of stay for all patients was 21 days. Bleeding was the most frequent adverse event. Stroke occurred in 4{\%} (bridge to transplantation) and 6{\%} (destination therapy) of patients. Quality-of-life measures and 6-minute walk distances showed sustained improvements throughout support. In conclusion, outcomes with LVAD support at open-heart centers are acceptable and comparable with results from the INTERMACS registry. With appropriate teams, training, center commitment, and certification, LVAD therapy is being disseminated in a responsible way to open-heart centers.",
author = "Katz, {Marc R.} and Dickinson, {Michael G.} and Raval, {Nirav Y.} and James Slater and Dean, {David A.} and Zeevi, {Gary R.} and Horn, {Evelyn M.} and Arash Salemi",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.amjcard.2015.02.010",
language = "English (US)",
volume = "115",
pages = "1254--1259",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9",

}

Outcomes of patients implanted with a left ventricular assist device at nontransplant mechanical circulatory support centers. / Katz, Marc R.; Dickinson, Michael G.; Raval, Nirav Y.; Slater, James; Dean, David A.; Zeevi, Gary R.; Horn, Evelyn M.; Salemi, Arash.

In: American Journal of Cardiology, Vol. 115, No. 9, 01.01.2015, p. 1254-1259.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Outcomes of patients implanted with a left ventricular assist device at nontransplant mechanical circulatory support centers

AU - Katz, Marc R.

AU - Dickinson, Michael G.

AU - Raval, Nirav Y.

AU - Slater, James

AU - Dean, David A.

AU - Zeevi, Gary R.

AU - Horn, Evelyn M.

AU - Salemi, Arash

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The goal of this study was to assess outcomes of patients who underwent implantation of left ventricular assist devices (LVADs) at nontransplantation mechanical circulatory support centers. As the availability of LVADs for advanced heart failure has expanded to nontransplantation mechanical circulatory support centers, concerns have been expressed about maintaining good outcomes. Demographics and outcomes were evaluated in 276 patients with advanced heart failure who underwent implantation of LVADs as bridge to transplantation or destination therapy at 27 open-heart centers. Baseline characteristics, operative mortality, length of stay, readmission rate, adverse events, quality of life, and survival were analyzed. The overall 30-day mortality was 3% (8 of 276), and survival rates at 6, 12, and 24 months, respectively, were 92 ± 2%, 88 ± 3%, and 84 ± 4% for the bridge-to-transplantation group and 81 ± 3%, 70 ± 5%, and 63 ± 6% for the destination therapy group, comparable with results published by the national Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). The median length of stay for all patients was 21 days. Bleeding was the most frequent adverse event. Stroke occurred in 4% (bridge to transplantation) and 6% (destination therapy) of patients. Quality-of-life measures and 6-minute walk distances showed sustained improvements throughout support. In conclusion, outcomes with LVAD support at open-heart centers are acceptable and comparable with results from the INTERMACS registry. With appropriate teams, training, center commitment, and certification, LVAD therapy is being disseminated in a responsible way to open-heart centers.

AB - The goal of this study was to assess outcomes of patients who underwent implantation of left ventricular assist devices (LVADs) at nontransplantation mechanical circulatory support centers. As the availability of LVADs for advanced heart failure has expanded to nontransplantation mechanical circulatory support centers, concerns have been expressed about maintaining good outcomes. Demographics and outcomes were evaluated in 276 patients with advanced heart failure who underwent implantation of LVADs as bridge to transplantation or destination therapy at 27 open-heart centers. Baseline characteristics, operative mortality, length of stay, readmission rate, adverse events, quality of life, and survival were analyzed. The overall 30-day mortality was 3% (8 of 276), and survival rates at 6, 12, and 24 months, respectively, were 92 ± 2%, 88 ± 3%, and 84 ± 4% for the bridge-to-transplantation group and 81 ± 3%, 70 ± 5%, and 63 ± 6% for the destination therapy group, comparable with results published by the national Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). The median length of stay for all patients was 21 days. Bleeding was the most frequent adverse event. Stroke occurred in 4% (bridge to transplantation) and 6% (destination therapy) of patients. Quality-of-life measures and 6-minute walk distances showed sustained improvements throughout support. In conclusion, outcomes with LVAD support at open-heart centers are acceptable and comparable with results from the INTERMACS registry. With appropriate teams, training, center commitment, and certification, LVAD therapy is being disseminated in a responsible way to open-heart centers.

UR - http://www.scopus.com/inward/record.url?scp=84927578108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927578108&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2015.02.010

DO - 10.1016/j.amjcard.2015.02.010

M3 - Article

C2 - 25772738

AN - SCOPUS:84927578108

VL - 115

SP - 1254

EP - 1259

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9

ER -